We evaluated the effect of lipid-based nanocarriers of different particle sizes (produced by different proportions of the same excipients in the formulations) loaded with the GLP-1 analog EXE, on gut hormone secretion and glucose tolerance in a HFD-induced obesity/diabetic model. Here, GCG is linked to obesity disorder.